Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 13/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MECP2 | P51608 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11987282 | 0.90 | ATR (0.47) | ATRNPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL11987280 | 0.83 | NPC1 (0.53) | ATRNPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL11987293 | 0.83 | ATR (0.41) | ATRNPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL11987294 | 0.83 | NPC1 (0.43) | ATRNPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL9885994 | 0.80 | MET (0.54) | METNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL11987261 | 0.80 | RAB9A (0.45) | ATRNPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL11987295 | 0.80 | ATR (0.46) | ATRNPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL11987292 | 0.77 | ATR (0.44) | ATRNPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL11987288 | 0.77 | TLR9 (0.47) | ATRNPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL11987284 | 0.75 | ATR (0.40) | ATRNPC1RAB9ASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247087-B2 | Compound having oxadiazole ring structure bonded with aromatic heterocyclic ring and organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8247087-B2 | Compound having oxadiazole ring structure bonded with aromatic heterocyclic ring and organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20090230849-A1 | COMPOUND HAVING OXADIAZOLE RING STRUCTURE BONDED WITH AROMATIC HETEROCYCLIC RING AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO., LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090230849-A1 | COMPOUND HAVING OXADIAZOLE RING STRUCTURE BONDED WITH AROMATIC HETEROCYCLIC RING AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO., LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090230849-A1 | COMPOUND HAVING OXADIAZOLE RING STRUCTURE BONDED WITH AROMATIC HETEROCYCLIC RING AND ORGANIC ELECTROLUMINESCENT DEVICE | OXA1L, ORC3, OCIAD1 | ATR 577/4885MET 4082/4885NPC1 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.